Caspian: Regenerating beta cells with a menin inhibitor
Kura Oncology spinout raised $50M to test whether an oral menin inhibitor can regrow patients’ own insulin-producing cells
Caspian is developing an oral menin inhibitor to regenerate patients’ own pancreatic beta cells, with plans to begin testing KO-7246 in healthy volunteers in 2027 and diabetes patients in 2028, executive chairman and co-founder Troy Wilson told BioCentury.
Caspian Therapeutics Inc. launched Sept. 9 as a spinout from Kura Oncology Inc. (NASDAQ:KURA), where Wilson is CEO, with a $50 million financing led by BVF Partners L.P. Other participants included T1D Fund, Invus, Montanova Capital LLC, Eli Lilly and Co. (NYSE:LLY), Kura, and certain Kura executives...